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Avascular necrosis (AVN) has been described as a complication of
combination chemotherapy, especially where it includes intermit-
tent high dose corticosteroids (Gogas and Fennelly, 1996; Harper
et al, 1984; Hui and Wiernik, 1996; Mould and Adam, 1983;
Perloff and Lesnick, 1980; Socie′ et al, 1994; Thorne et al, 1981;
Tombolini et al, 1992). We have recently reported five patients
treated with chemotherapy for testicular tumours who developed
symptomatic avascular necrosis following chemotherapy with
steroids used as an antiemetic (Cook et al, 1999). 
In this study we aim to assess the prevalence of avascular
necrosis in patients who have received first line chemotherapy for
testicular tumours. 
MATERIALS AND METHODS 
All patients who had completed at least two cycles of first line
chemotherapy in the 5 years prior to the start of the study who
have remained relapse free and had at least 6 months follow up
(March 1993–September 1997) were asked to participate in this
study. After giving written consent they completed a questionnaire
regarding hip pain and risk factors for AVN and were asked to
have magnetic resonance imaging (MRI) scan. T1 (TE = 12 ms,
TR = 600 ms, 150 degree flip angle, 5 mm slice thickness to no
intergap, 192 × 256 matrix size, 3 excitations) and short time in
version recovery (TE = 60 ms, TR = 4230 ms, TI = 150 ms, 5 mm
slice thickness, 198 × 256 matrix size, 1 excitation matrix size)
sequences were performed in the coronal plane through the hip
joints, the field of view included the proximal femora and pelvis. 
Time to AVN was calculated using the methods of Kaplan and
Meier (1958) using the time from chemotherapy to diagnosis of
AVN as the endpoint. Patients with no AVN were censored at the
date of enrolment to the study. 
RESULTS 
Of the 103 eligible patients who were contacted, 63 returned ques-
tionnaires. The median follow-up of patients invited for screening
was 32 months (range 7.1–65 months) their characteristics are
described in Table 1. In this cohort were two of the cases we had
previously reported to have bilateral AVN of the hips (Cook et al,
1999). To avoid bias they were included in the analysis as they
satisfied the eligibility criteria for the study. One further patient
informed us that he had recently been diagnosed as having AVN of
both hips on MRI at another hospital. These images were reviewed
and the diagnosis confirmed. Sixteen patients did not have MRI
scans because of failure to attend or being unsuitable due to
metallic implants. 
Of the 44 patients imaged one was found to have avascular
necrosis in both hips with changes indicative of active disease. This
patient had been experiencing bilateral hip pain for several weeks,
which had previously been undiagnosed. All four patients with AVN
had had bilateral hip pain. Two additional patients described bilateral
hip pain but did not attend for MRI scanning. Seven patients
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Table 1 Patient characteristics 
Number of patients sent questionnaire 103 
Age (median) 30 (range 16–59) 
Chemotherapy regime
BEP 2 cycles 21 
BEP 3–4 cycles 52 
C-BOP BEP 19 
BOP 2 cycles 5 
*Steroid dose (mean (range)) 2.25 g (0.76–3.86 g) 
*Converted to equivalent dose of prednisolone. 
B, Bleomycin; C, Carboplatin; P, Cisplatin: E, Etoposide; O, vincristine. 
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described unilateral or non specific hip pain; six attended for MRI,
none of whom had avascular necrosis. The frequency of AVN in the
patients undergoing MR examination was 4/47 (9%, CI 2–20). AVN
was diagnosed, at a median of 21 months (range 14–32 months) after
commencement of chemotherapy. 
If it is assumed that all affected patients were symptomatic and
that all symptomatic patients attended for MR examination, the
overall prevalence was 4/103 (3.8%, CI 1–10%). As not all
patients had completed the at risk period this equates to a 3-year
actuarial risk of 6.3% (95% confidence limits (CI) 2.4–16.1)
(Figure 1). 
The affected patients received BEP chemotherapy either four
cycles or three cycles and received total steroid doses equivalent to
2.97 g, 2.49 g, 3.3 g and 1.45 g of prednisolone respectively (mean
2.55 g). Thus three of the four patients received above the mean
dose (2.25 g) of steroids administered. These three patients had no
known predisposing factors for AVN. The patient who received
the equivalent of 1.45 g of prednisolone had a high alcohol intake,
a known predisposing factor to AVN (Mirzai et al, 1998).
However, the number of events are too small to draw any mean-
ingful conclusions. 
DISCUSSION 
Our results demonstrate that patients receiving chemotherapy for
testicular tumours, when dexamethasone is used as an anti-emetic,
may develop avascular necrosis. It can be presumed that the same
would be true for other patients treated for solid tumours. 
We have tried to estimate the importance of this complication by
documenting the frequency with which it occurs in one specific
group of patients with testicular tumours. The prevalence of AVN in
this study may be as high as 9% (CI 2–20%). All affected patients in
our study were symptomatic and, if we assume that patients with hip
pain were more likely to return questionnaires and attend for MR
examination then the prevalence could be quoted as 3.8% (CI
1–10%). On actuarial analysis this equates to a 3-year risk of 6.3%
(95% CI 2.4–16.1). It does seem more likely that patients with symp-
toms would have attended for MR examinations and indeed 13 of the
47 patients (28%) who did attend had noticed some hip pain. The
prevalence of pain in patients not returning questionnaires is not
known. However, it is interesting to note that 3 of the 16 patients
(19%) who returned questionnaires but did not have MRI had
described hip pain and in 2 of these the pain was bilateral. 
A potential criticism of this study is that of bias in the sample. It
was the recent diagnosis of AVN in several patients (Cook et al,
1999) that persuaded us to look at the problem in more depth. 
We tried to eliminate bias by approaching all eligible patients who
had received chemotherapy within a recently treated cohort. Two
of the previously diagnosed patients were included as they were
treated within the time period of the study. Before undertaking this
study we had not been aware of the diagnosis of AVN in the other
two patients. If our previously identified patients are excluded the
incidence of AVN is still in the order of 2% (2/101). 
There is a recognized association of avascular necrosis and
steroid use. Avascular necrosis has been reported when steroids are
used with chemotherapy as part of the treatment regime for
tumours such as lymphomas (Gogas and Fennelly, 1996; Hui and
Wiernik, 1996; Mould and Adam, 1983; Perloff and Lesnick, 1980;
Socie′ et al, 1994; Thorne et al, 1981; Tombolini et al, 1992). Our
data and that from scattered case reports suggest that chemotherapy
with steroids used as anti-emetics carries a significant risk of AVN.
With the exception of the one case where there was a history of
alcohol abuse all patients developing AVN in this study and in our
previous report (Cook et al, 1999) received above our the mean
steroid dose (2.25 g), raising the question as too whether there
could be a dose response relationship for the development of AVN.
However as AVN has been described in patients treated with
chemotherapy without steroids (Harper et al, 1984) it is possible the
situation may be more complex than a pure steroid related effect. 
Relatively high doses of dexamethasone in combination with
5HT3 antagonists have been shown to be a high effective regime
for controlling nausea in highly emetogenic regimens and are
being used routinely as such.
This data has implications for this practice. 
  As there is little evidence for an anti-emetic dose response for
the dexamethasone when it is used with 5HT3 antagonists; it
would be worth considering whether equivalent antiemesis
could be obtained with a lower risk of AVN by using protocols
with lower steroid doses. 
  Patients who developed hip pain after chemotherapy warrant
further investigation with plain radiographs and/or MRI. 
  Patients receiving high dose steroids as anti-emetics should be
warned of the risk of avascular necrosis so as to be able to
make an informed choice. 
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